Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HARMONYL vs APRESOLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased peripheral resistance and blood pressure. The exact molecular mechanism is unclear but may involve interference with calcium movement or inhibition of inositol trisphosphate-induced calcium release.
Hypertension (FDA-approved),Off-label: Management of opioid withdrawal symptoms, treatment of attention deficit hyperactivity disorder (ADHD), and reduction of menopausal hot flashes
Hypertension (oral, as adjunctive therapy),Severe hypertension or hypertensive emergency (parenteral)
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
Initial: 10 mg oral 4 times daily for 2-4 days; increase to 25 mg 4 times daily for the first week. Maintenance: 50 mg 4 times daily; maximum 300 mg/day. IV: 20-40 mg IM or slow IV push, repeat as needed.
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
Terminal elimination half-life is 3-7 hours in patients with normal renal function; prolonged to 7-16 hours in renal impairment. Acetylator phenotype affects half-life: in slow acetylators, half-life may be 4-5 hours; in fast acetylators, 1-2 hours, but clinical effect (antihypertensive) lasts longer due to persistent binding to vascular tissue.
Hepatic metabolism via glucuronidation and sulfation; CYP450 enzymes not significantly involved.
Extensively metabolized in the liver via acetylation (N-acetyltransferase, NAT2) and oxidation (CYP450, primarily CYP3A4 and CYP2C19).
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Primarily renal; 86-90% of an oral dose is excreted in urine as metabolites (N-acetylhydralazine, hydralazine pyruvic acid hydrazone) and unchanged drug (<10% unchanged); biliary/fecal excretion is minimal (<10%).
95% bound primarily to albumin and alpha-1-acid glycoprotein
87-90% bound to plasma proteins, primarily albumin; binding is reduced in uremia.
1.2–1.8 L/kg (mean 1.5 L/kg); indicates extensive tissue distribution
1.5-1.8 L/kg; distributes widely into total body water, with high affinity for vascular smooth muscle, where it accumulates; Vd is larger in slow acetylators due to higher free drug levels.
Oral: 75%; IM: 90%
Oral immediate-release: 30-50% in fast acetylators; 50-75% in slow acetylators. Bioavailability is increased when taken with food (peak concentration enhanced 50-70%).
GFR ≥ 30 m L/min: no adjustment. GFR 15-29 m L/min: reduce to 12.5 mg once daily. GFR < 15 m L/min: not recommended.
Cr Cl 10-50 m L/min: administer every 8 hours. Cr Cl <10 m L/min: administer every 8 hours or reduce dose by 50%.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 12.5 mg once daily. Child-Pugh C: contraindicated.
Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Weight < 30 kg: not established. Weight ≥ 30 kg: 0.5 mg/kg orally once daily, up to 25 mg maximum.
Oral: 0.75-3 mg/kg/day in 2-4 divided doses, maximum 7.5 mg/kg/day or 200 mg/day. IV: 0.1-0.2 mg/kg/dose every 4-6 hours as needed.
Initiate at 12.5 mg once daily; increase cautiously to 25 mg once daily based on tolerability and renal function.
Start at 10 mg 2-3 times daily; increase gradually to avoid hypotension. Maximum 200 mg/day. Monitor for orthostatic hypotension and reflex tachycardia.
Abrupt discontinuation may cause rapid rise in blood pressure (rebound hypertension) and symptoms of sympathetic overactivity (e.g., nervousness, agitation, headache). This is particularly dangerous in patients on high doses or concurrent beta-blocker therapy.
None.
Rebound hypertension upon abrupt withdrawal; caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure; may cause sedation and dry mouth; use caution in patients with history of depression.
May cause drug-induced lupus erythematosus, especially in slow acetylators; monitor for symptoms. Use cautiously in patients with coronary artery disease (may cause reflex tachycardia and exacerbate angina). Can cause peripheral neuritis (pyridoxine deficiency), alone with high doses. May cause sodium and water retention, requiring concomitant diuretic therapy.
Hypersensitivity to clonidine or any component; use with MAO inhibitors (hypertensive crisis risk); noncompliant patients who may abruptly discontinue therapy (risk of rebound hypertension).
Hypersensitivity to hydralazine or any component of the formulation. Mitral valve rheumatic heart disease. Aortic aneurysm (theoretical contraindication due to increased cardiac output/loading conditions).
Avoid tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) due to risk of hypertensive crisis. Limit alcohol intake as it may enhance orthostatic hypotension.
Food may increase bioavailability of hydralazine; take with food to reduce peak concentrations and potential side effects. Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) if taking MAOIs concurrently. No specific dietary restrictions otherwise.
FDA Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and cleft palate due to folate antagonism. Second and third trimesters: risk of oligohydramnios, fetal renal dysfunction, and premature closure of ductus arteriosus if used after 30 weeks gestation.
First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but risk cannot be excluded. Second and third trimesters: May cause fetal tachycardia, neonatal hypotension, and ileus; associated with maternal hypotension and potential uteroplacental insufficiency. FDA Pregnancy Category C.
Contraindicated during breastfeeding. M/P ratio: not determined. Excreted in human milk in low concentrations, but potential for serious adverse reactions in nursing infants, including hemolytic anemia and kernicterus due to sulfonamide component.
Minimal excretion into breast milk; M/P ratio approximately 1.0. Considered compatible with breastfeeding by the American Academy of Pediatrics; monitor infant for hypotension and feeding difficulties.
No established safe dose. Drug should be avoided during pregnancy. If unavoidable, use lowest effective dose for shortest duration. Trimethoprim component may require dose reduction due to increased glomerular filtration rate in pregnancy, but specific adjustment not validated. Sulfamethoxazole dose unchanged.
No standard dose adjustment recommended; however, increased plasma volume may necessitate higher doses. Monitor response and titrate to effect; avoid severe hypotension to prevent uteroplacental hypoperfusion.
Harmonyl is a brand name for deserpidine, a Rauwolfia alkaloid used as an antihypertensive. It depletes catecholamines and serotonin from central and peripheral nerve endings. Onset of action is 1-2 weeks. Avoid in patients with history of depression, peptic ulcer, or pheochromocytoma. Monitor for bradycardia and hypotension. May cause extrapyramidal symptoms. Use with caution with MAOIs; avoid concurrent use.
Hydralazine (Apresoline) is a direct-acting vasodilator primarily used for hypertension management, especially in preeclampsia and hypertensive emergencies. It can cause a lupus-like syndrome, especially in slow acetylators; testing for N-acetyltransferase 2 (NAT2) phenotype may be considered. Tachyphylaxis can occur; concomitant beta-blocker and diuretic therapy are often required. Onset of action is 10-20 minutes IV, 20-30 minutes IM. Avoid in patients with coronary artery disease due to reflex tachycardia.
Take this medication exactly as prescribed, usually once daily.,Do not stop taking this medication abruptly; sudden withdrawal can cause severe hypertension.,You may experience dizziness or drowsiness; avoid driving or operating machinery until you know how the medication affects you.,Avoid alcohol while taking this medication.,Report any signs of depression, unusual mood changes, or difficulty sleeping to your doctor.,If you have a history of stomach ulcers, inform your doctor before starting this medication.,Keep all appointments for blood pressure monitoring.
Take exactly as prescribed; do not stop suddenly as this can cause a rapid rise in blood pressure.,May cause dizziness or lightheadedness; avoid driving or operating machinery until you know how this medicine affects you.,Report any unexplained joint pain, fever, chest pain, or rash to your doctor immediately as these may be signs of a serious reaction (drug-induced lupus).,Avoid alcohol consumption as it can increase the blood pressure lowering effects and dizziness.,Do not take over-the-counter cold, sinus, or weight loss products without checking with your doctor, as many contain ingredients that can raise blood pressure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HARMONYL vs APRESOLINE, answered by our medical review team.
HARMONYL is a Antihypertensive that works by Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.. APRESOLINE is a Antihypertensive that works by Direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased peripheral resistance and blood pressure. The exact molecular mechanism is unclear but may involve interference with calcium movement or inhibition of inositol trisphosphate-induced calcium release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HARMONYL and APRESOLINE depend on the specific clinical indication. These are both Antihypertensive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HARMONYL is: 25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.. The standard adult dose of APRESOLINE is: Initial: 10 mg oral 4 times daily for 2-4 days; increase to 25 mg 4 times daily for the first week. Maintenance: 50 mg 4 times daily; maximum 300 mg/day. IV: 20-40 mg IM or slow IV push, repeat as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HARMONYL and APRESOLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HARMONYL is classified as Category C. FDA Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and cleft palate due to folate antagonism. Second and third trimesters: . APRESOLINE is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but risk cannot be excluded. Second and third trimesters: May cause fetal t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.